Med24
Clinical Medicine 28. 10. 2026 • 1 min read • MedPage Today

RFK Jr. Eases Access to Unproven Peptides Despite Opposition From FDA Scientists

The Trump administration on Wednesday acted to ease access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr., and FDA scientific staffers had little input on the decision and opposed the changes, according...

RFK Jr. Eases Access to Unproven Peptides Despite Opposition From FDA Scientists

A policy issued by the Department of Health and Human Services (HHS), spearheaded by Robert F. Kennedy Jr., aims to ease access to unproven peptide drugs. This policy directs the Food and Drug Administration (FDA) not to take action against specialty pharmacies selling a handful of peptides, including BPC-157, TB-500, and KPV.

Sponsored content

FDA and HHS Involvement

These chemicals are currently considered illegal drugs by the FDA because they have not undergone the agency’s rigorous review process for safety and effectiveness. The policy reflects Kennedy’s determination that it advances patient choice and protects Americans from online peptide sales. FDA scientific staffers opposed the changes, citing concerns about undermining the agency’s mission to limit unproven health products. HHS officials initially sought a regulation allowing these peptides to be used by compounding pharmacies, but this approach was abandoned.

Original Scientific Source
MedPage Today
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement